Derek Cowsert

News

Tumor-Infiltrating Lymphocytes Exhibit Prognostic Value in Low-Risk Ductal Carcinoma in Situ

08/25/2022

Study findings demonstrate the efficacy of tumor-infiltrating lymphocytes for predicting prognoses in patients with low-risk ductal carcinoma in situ.

Study findings demonstrate the...

08/25/2022

Oncology

News

High Tumor Mutational Burden Associated With Improved Progression-Free Survival Among Patients With NSCLC

02/16/2023

Derek Cowsert ;

A study found high tumor mutational burden to be associated with improved local-regional control and progression-free survival among patients with non-small cell lung cancer treated with chemoradiation and durvalumab.

A study found high tumor...

02/16/2023

Oncology

News

Epigallocatechin-3-Gallate Plus Radiotherapy Reduces Radiation-Induced Dermatitis in Patients With Breast Cancer

06/14/2022

Derek Cowsert ;

Epigallocatechin-3-gallate plus radiotherapy reduced radiation-induced dermatitis vs radiotherapy alone among patients with breast cancer in a phase 2 study.

Epigallocatechin-3-gallate plus...

06/14/2022

Oncology

News

High Tumor Mutation Burden Associated With Improved Clinical Outcomes of Immune Checkpoint Inhibitors in NSCLC

10/25/2022

Derek Cowsert ;

A multicenter cohort study identified TMB levels are associated with objective response rate, progression-free survival, and overall survival among patients who received PD-1/PD-L1 inhibition as treatment for advanced NSCLC.

A multicenter cohort study...

10/25/2022

Oncology

News

HER2-E Biomarker Associated With Poor Aromatase Inhibitor Response and Worse Outcomes in ER-Positive/HER2-Positive Breast Cancer

11/11/2022

Derek Cowsert ;

HER2-E and ERBB2 biomarkers play a role in resistance to aromatase inhibitors, as well as a higher risk of recurrence in patients with ER+/HER2+ breast cancer.

HER2-E and ERBB2 biomarkers play...

11/11/2022

Oncology

News

IHC Can Select Best Endometrial Cancer Candidates for Bevacizumab Plus Chemotherapy

07/28/2022

Derek Cowsert ;

Determining p53 status by IHC can help select the patients with endometrial cancer most likely to experience survival benefit when treated with bevacizumab plus chemotherapy, according to a phase 2 study.

Determining p53 status by IHC...

07/28/2022

Oncology

News

FDA Approves Tremelimumab Plus Durvalumab and Platinum-Based Chemotherapy for Metastatic NSCLC

11/11/2022

Derek Cowsert ;

On November 10, 2022, the FDA granted approval to tremelimumab, in combination with durvalumab and platinum-based chemotherapy, for adult patients with metastatic NSCLC without an EFGR mutation or ALK aberrations.

On November 10, 2022, the FDA...

11/11/2022

Oncology

News

Osimertinib for Patients With Progressive EGFR-Mutated T790M-Negative NSCLC

04/21/2023

Derek Cowsert ;

Osimertinib demonstrated modest antitumor activity in patients with EGFR-mutated T790M-negative non-small cell lung cancer that has progressed after treatment, according to a phase 2 study.

Osimertinib demonstrated modest...

04/21/2023

Oncology

News

Pembrolizumab Plus Chemotherapy Improves OS vs Chemotherapy and Placebo in Advanced Triple-Negative Breast Cancer

08/25/2022

Derek Cowsert ;

In a phase 3 study, pembrolizumab plus chemotherapy prolonged OS vs chemotherapy plus placebo among patients with advanced triple-negative breast cancer.

In a phase 3 study,...

08/25/2022

Oncology

Conference Coverage

Optimal Treatment Modality for Patients With Advanced Cervical Cancer

02/23/2023

Derek Cowsert ;

Data presented at the 2023 ESMO Gynecological Cancers Congress shows survival outcomes were improved among patients with late-stage cervical cancer who received adjuvant chemoradiotherapy compared with other treatment modalities.

Data presented at the 2023 ESMO...

02/23/2023

Oncology